6 citations
,
January 1999 in “Dermatology” Alopecia areata is linked to autoimmune antibodies.
3 citations
,
October 2022 in “Journal of Cosmetic Dermatology” CAR is a useful marker for assessing alopecia areata severity.
October 2022 in “The American journal of gastroenterology” Thymoma-associated multiorgan autoimmunity can cause liver damage and affects multiple organs, with limited treatment options and a generally poor prognosis.
January 2008 in “Bradford Scholars (University of Bradford)” Alopecia areata may be caused by antibodies targeting specific hair follicle proteins, hindering hair growth.
6 citations
,
June 2011 in “British Journal of Dermatology” People with alopecia areata have higher levels of RBP4 protein and antibodies against it.
April 2023 in “Dermatology practical & conceptual” Some patients with hair loss after mild COVID-19 had positive tests for certain autoantibodies.
June 2025 in “JCEM Case Reports” False high testosterone levels were corrected using a more accurate test.
January 2025 in “Dermatologic Therapy” Alopecia areata may be linked to higher heart disease risk.
October 2024 in “Journal of the Endocrine Society” Recognizing macro-TSH is crucial to avoid unnecessary treatments.
May 2023 in “The Journal of Immunology” Alopecia areata involves unique activation of certain immune cells.
April 2020 in “International Journal of Dermatology” T-cell patterns in skin help distinguish alopecia areata from androgenetic alopecia.
June 2020 in “Jurnal Penyakit Dalam Indonesia” Anti-DFS70 antibodies can help identify nonsystemic autoimmune conditions in SLE patients.
2 citations
,
January 2014 in “Türkiye klinikleri tıp bilimleri dergisi” Thyroid autoimmunity may be involved in some female hair loss, suggesting the need to test for thyroid antibodies in these patients.
15 citations
,
November 2015 in “International Journal of Dermatology” Keratin 14 may be an autoantigen in autoimmune skin diseases.
21 citations
,
January 2021 in “Journal of infection and chemotherapy” Men, diabetes, and high inflammation levels lead to higher COVID-19 antibodies.
1 citations
,
November 2018 in “immuneACCESS” Expanded CD8+ T cells are linked to Alopecia Areata and may cause relapse after treatment.
3 citations
,
February 2022 in “Journal of Infection” People with no symptoms or mild COVID-19 have lower antibody levels, increasing their risk of getting COVID-19 again.
66 citations
,
July 2010 in “Journal of Proteome Research” Trichohyalin may trigger the immune response causing alopecia areata.
12 citations
,
January 2014 in “Annals of Dermatology” Modified superoxide dismutase may trigger an autoimmune response in alopecia areata.
January 2014 in “Journal of Jilin University” Higher levels of certain immune cells and proteins are linked to more severe lupus symptoms.
2 citations
,
August 2020 in “Journal of Cosmetic Dermatology” Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.
6 citations
,
January 2024 in “International Journal of Dermatology” Monoclonal antibodies are often linked to alopecia areata cases.
April 2025 in “Dermatology Practical & Conceptual” Alopecia areata patients have higher systemic inflammation, even in mild cases.
38 citations
,
September 2004 in “Journal of Autoimmunity” Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.
June 2025 in “Medical Science Journal for Advance Research” Higher levels of MIG and IP-10 may help diagnose and monitor Alopecia Areata.
3 citations
,
February 2025 in “Endocrine” Confirm testosterone levels with advanced tests to avoid unnecessary procedures.
April 2023 in “Journal of Investigative Dermatology” Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.
13 citations
,
September 2013 in “Steroids” The DHT immunoassay is unreliable due to high cross-reactivity with testosterone.
September 2024 in “Archives of Medical Science” Alopecia areata is linked to immune system differences, with specific biomarkers like CXCL9 and CXCL10 being key for diagnosis and potential treatment targets.
July 2024 in “Clinical Case Reports” ANA-negative lupus nephritis can be diagnosed and treated effectively with a comprehensive approach.